Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
16 hedge funds and large institutions have $588K invested in Plus Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 7 closing their positions.
0.01% less ownership
Funds ownership: 0.02% → 0.02% (-0.01%)
27% less funds holding
Funds holding: 22 → 16 (-6)
33% less capital invested
Capital invested by funds: $872K → $588K (-$284K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$66.7K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$9.15K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$673 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$185K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$60.4K |
| 3 |
Millennium Management
New York
|
-$24.1K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$7.92K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6.86K |
PSTV Hedge Fund Activity: Q1 2023 in Review
16 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q1 2023, worth a combined $588K — down 33% from $872K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PSTV and 1 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $66.7K. The largest seller was Parkman Healthcare Partners, exiting entirely with an estimated $185K sold.
- 16 institutional investors held Plus Therapeutics (PSTV) as of Q1 2023, down from 22 in Q4 2022.
- Funds reported $588K of Plus Therapeutics stock for Q1 2023, down 33% quarter-over-quarter.
- 1 fund opened new Plus Therapeutics positions in Q1 2023 and 7 closed out, a net change of -6 holders.
- The largest Plus Therapeutics buyer in Q1 2023 was Renaissance Technologies, an estimated $66.7K added.
- The largest Plus Therapeutics seller in Q1 2023 was Parkman Healthcare Partners, an estimated $185K sold.
Based on aggregated 13F filings for Q1 2023.